sotalol has been researched along with Failure to Thrive in 1 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Failure to Thrive: A condition of substandard growth or diminished capacity to maintain normal function.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakurai, K | 1 |
| Takahashi, K | 1 |
| Nakayashiro, M | 1 |
1 other study available for sotalol and Failure to Thrive
| Article | Year |
|---|---|
Combined flecainide and sotalol therapy for multifocal atrial tachycardia in cardio-facio-cutaneous syndrome.
Topics: Anti-Arrhythmia Agents; Drug Therapy, Combination; Ectodermal Dysplasia; Electrocardiography; Facies | 2018 |